3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
3
Withdrawn
1
Unknown
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Conditions
Multiple Myeloma
37
Neoplasms, Plasma Cell
11
Recurrence
6
Lymphoma, Mantle-Cell
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Peripheral Nervous System Diseases
2
Lymphoma, Large B-Cell, Diffuse
2
Leukemia, Myeloid, Acute
2
Immunoglobulin Light-chain Amyloidosis
2
Glioblastoma
2
Waldenstrom Macroglobulinemia
1
Renal Insufficiency
1
Rectal Neoplasms
1
Pathologic Complete Response
1
Paraproteinemias
1
Pancreatic Neoplasms
1
Ovarian Neoplasm Epithelial
1
Neoplasms by Histologic Type
1
Neoplasms
1
Neoplasm, Residual
1
Mesothelioma, Malignant
1
Mesothelioma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Liver Neoplasms
1
Leukemia, Promyelocytic, Acute
1
Leukemia, Plasma Cell
1
Leukemia
1
Hypoxia
1
Interventions
Dexamethasone
2
liposomal doxorubicin
1
fludarabine phosphate
1
fludarabine
1
Melphalan
1
Maintenance
1
Calcium Dobesilate
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Leukemia, Plasma Cell
×
Bortezomib
×
Clear all
NCT01328236
2011-09-22
Bortezomib
Clinical Service, China
Phase 2
Unknown
20 enrolled